After-hours movers: Palantir, Hims &amp; Hers, Vertex Pharma and more\n\nAuthorLouis Juricic\nStock Markets\nPublished 04/08/2025, 22:10After-hours movers: Palantir, Hims &amp; Hers, Vertex Pharma and more\n\nAfter-hours movers:\n\nPalantir (NASDAQ:PLTR) rose 4.5% after second quarter results beat estimates on the top and bottom line, and it reported strong guidance. Revenue grew 48% year-over-year and 14% quarter-over-quarter to $1.004 billion.\n\nHims &amp; Hers Health (HIMS) fell 11% after reporting mixed results. Despite a bottom line beat, it reported revenue that missed estimates. \n\nVertex Pharma (NASDAQ:VRTX) declined 7% after it halted VX-993 development after its pain study missed the primary endpoint.\n\nBioMarin Pharma (BMRN) rose 4.8% strong quarterly results and guidance. Revenue rose 16% year-over-year. \n\nKyndryl (KD) fell 7% after quarterly revenue trailed consensus estimates. \n\nSemrush (SEMR) declined 14% after disappointing second quarter results. \n\n\nShould you invest $2,000 in VRTX right now?\n\nWith VRTX making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed VRTX alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including VRTX, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is VRTX poised for similar growth? Don't miss the opportunity to find out.

After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more

The article highlights stock price movements for several companies following their quarterly financial results, including Palantir's 4.5% rise due to strong earnings, Hims & Hers Health's 11% drop after mixed results, and Vertex Pharma's 7% decline after halting a drug trial. It also mentions BioMarin's 4.8% gain and Kyndryl's 7% fall.